Good find DanielGuda. I know zero about MaB's. Apparently MaB's and Car-T work in very different ways. I found this conclusion quote below on a paper comparing the two...
Furthermore we will also be getting it into Car- NK's and maybe we could even see Car-M's (Macrophages) through a partnership or even our own M programs you just never know what else CHM may license.
"After some initial negative clinical experiences, (I assume they are referring to first gen Car-T's in solid tumors) CAR-T cell therapies represent now a very solid approach and a real hope for the future of cancer immunotherapies. Because CAR-based therapies are strictly linked from mAb-based therapies, at least in term of antigen specificity, we need to seek whether CAR-T cells offer sufficient advantages to justify the need for a personalized medicine, since CAR-T cells need to be manufactured for each single patient while mAbs are off-the shelf reagents. Preliminary evidences are, at least in part, in favor of suggesting the superior role of CAR-T cells to mAbs, since the former can promote self amplification and sustained effects, and can recognize tumor cells with antigen expression at levels that can elude mAb’s recognition. However, whether adoptively transferred CAR-T cells are superior to mAbs in term of biodistribution to the tumor still requires a robust demonstration although essential to develop effective strategies especially for solid tumors. The proposed engineering of CAR-T cells to optimize their trafficking to the tumor environment represents a potential way to achieve this desired effect. Finally, greater efficacy frequently comes with toxicities, and in the specific case of CAR-T cells, these toxicities cannot be necessarily anticipated from the previous and safe use of a mAb specific for the same target due to the intrinsic functional activity of T cells to which the CAR molecule are engaged. Thus a very careful selection of the target antigen must be used in case of CAR-T-cell based therapies"
In relation to careful selection, In CDH17's case as a selected target, all these types of tumors we are targeting in the trials express high levels of CHD-17, in a very high percentage of tumor cells.
CHM Price at posting:
15.0¢ Sentiment: Buy Disclosure: Held
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)